{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T16:45:24Z","timestamp":1782665124453,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.lungcan.2026.109406","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T08:09:04Z","timestamp":1775808544000},"page":"109406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Regional variations in molecular testing and treatment of patients with metastatic NSCLC in the Netherlands"],"prefix":"10.1016","volume":"216","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8121-7602","authenticated-orcid":false,"given":"Jente M.","family":"Klok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.L. Rana","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marthe S.","family":"Paats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0660-0221","authenticated-orcid":false,"given":"Anouk H.","family":"Eijkelboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.","family":"von der Th\u00fcsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester F.","family":"Lingsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim G.J.V.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"van Klaveren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7689","key":"10.1016\/j.lungcan.2026.109406_b0005","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109406_b0010","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109406_b0015","unstructured":"IKNL. Incidence Lungcancer. 2024 13-08-2024]; Available from: https:\/\/iknl.nl\/kankersoorten\/longkanker\/registratie\/incidentie."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109406_b0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1200\/JCO.2015.62.0138","article-title":"Extended survival and prognostic factors for patients with ALK-rearranged non\u2013small-cell lung cancer and brain metastasis","volume":"34","author":"Johung","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109406_b0025","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jtho.2015.12.103","article-title":"Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs","volume":"11","author":"Lin","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109406_b0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jtho.2021.08.011","article-title":"Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis","volume":"17","author":"Planchard","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109406_b0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109406_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114125","article-title":"Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands","volume":"205","author":"de Jager","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109406_b0045","unstructured":"Specialists, D.F.o.M. Non-Small Cell Lung Cancer\u2014General Guideline. 2020 [cited 2024 July, 1st]; Available from: https:\/\/richtlijnendatabase.nl\/richtlijn\/niet_kleincellig_longcarcinoom\/algemeen.html."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109406_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101628","article-title":"Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe","volume":"8","author":"Hofman","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2026.109406_b0055","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.2147\/OTT.S313669","article-title":"Testing for EGFR mutations and ALK rearrangements in advanced non-small-cell lung cancer: considerations for countries in emerging markets","author":"Dalurzo","year":"2021","journal-title":"OncoTargets Therapy"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109406_b0060","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/annonc\/mdv208","article-title":"Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer","volume":"26","author":"Lim","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109406_b0065","doi-asserted-by":"crossref","unstructured":"Hendriks, L.E.L., et al., Lung cancer in the Netherlands. 2021, Elsevier. p. 355-365.","DOI":"10.1016\/j.jtho.2020.10.012"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109406_b0070","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/ije\/22.3.369","article-title":"Completeness of cancer registration in Limburg","volume":"22","author":"Schouten","year":"1993","journal-title":"The Netherlands. Int J Epidemiol"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109406_b0075","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ccm.2020.02.006","article-title":"Lung Cancer Staging","volume":"41","author":"Tanoue","year":"2020","journal-title":"Clin. Chest Med."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109406_b0080","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jtho.2018.05.030","article-title":"Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC","volume":"13","author":"Rolfo","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109406_b0085","unstructured":"SONCOS, Normeringsrapport. 2022."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109406_b0090","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.42970","article-title":"Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non\u2013small cell lung cancer","volume":"7","author":"Owen","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.lungcan.2026.109406_b0095","unstructured":"R, T., RStudio: Integrated Develo0pment Environment for R. 2021, RStudio, PBC, Boston, MA."},{"key":"10.1016\/j.lungcan.2026.109406_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","author":"Meyer","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.lungcan.2026.109406_b0105","doi-asserted-by":"crossref","first-page":"e1347","DOI":"10.1002\/onco.13580","article-title":"Multicenter comparison of molecular tumor boards in the Netherlands: definition, composition, methods, and targeted therapy recommendations","volume":"26","author":"Koopman","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2026.109406_b0110","first-page":"D1607","article-title":"National variation in molecular diagnostics in metastatic lung cancer","volume":"162","author":"Kuijpers","year":"2018","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"10.1016\/j.lungcan.2026.109406_b0115","article-title":"Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer","volume":"38","author":"de Jager","year":"2024","journal-title":"Lancet Region. Health-Europe"},{"key":"10.1016\/j.lungcan.2026.109406_b0120","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdv128.04","article-title":"EGFR mutation testing and oncologist treatment choice in advanced NSCLC: global trends and differences","volume":"26","author":"Spicer","year":"2015","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109406_b0125","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cllc.2017.04.004","article-title":"Genomic profiling of advanced non\u2013small cell lung cancer in community settings: gaps and opportunities","volume":"18","author":"Gutierrez","year":"2017","journal-title":"Clin. Lung Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109406_b0130","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/thoraxjnl-2021-218059","article-title":"Impact of time-to-treatment on survival for advanced non-small cell lung cancer patients in the Netherlands: a nationwide observational cohort study","volume":"78","author":"Klarenbeek","year":"2023","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109406_b0135","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S1470-2045(16)00077-2","article-title":"Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2026.109406_b0140","unstructured":"Claus, P.-E., Toepassing van circulerend cel-vrij DNA in plasma als \u2018liquid biopsy\u2019voor solide tumoren. 2016."},{"key":"10.1016\/j.lungcan.2026.109406_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113911","article-title":"Sotorasib in KRAS G12C-mutated non-small cell lung cancer: a multicenter real-world experience from the compassionate use program in Germany","volume":"201","author":"Stratmann","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109406_b0150","unstructured":"van der Woerd, O., Sleijfer S. Opinie: Het debat over netwerkvorming is aan verrijking toe. 2024 [cited 2024 24 September]; Available from: https:\/\/www.zorgvisie.nl\/blog\/opinie-het-debat-over-netwerkvorming-is-aan-verrijking-toe\/."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T16:21:45Z","timestamp":1782663705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226004678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":30,"alternative-id":["S0169500226004678"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109406","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regional variations in molecular testing and treatment of patients with metastatic NSCLC in the Netherlands","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109406","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109406"}}